Diabetes drug showdown: which combo sheds more pounds?

NCT ID NCT07247656

Completed Disease control Sponsor: Bahria University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested two different drug combinations in 200 adults with type 2 diabetes to see which helped reduce body weight more. Participants took either empagliflozin plus linagliptin or empagliflozin plus metformin for 12 weeks. Researchers measured changes in weight, blood sugar, and waist size.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin, linagliptin, metformin
What this could lead to: If one combination works better, it could offer a more effective weight-loss option for people with type 2 diabetes.
What could go wrong: This is a small, short-term study (12 weeks) with only 200 participants. Results may not apply to everyone, and side effects like low blood sugar are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS

Contacts and locations

Locations

Bahria University

Karachi, Sindh, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.